The global celiac disease Drugs market size was worth US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2022-2029).
Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers.
The global celiac disease drugs market growth is driven by the increasing prevalence of celiac diseases population. In addition, strong research and development activities to bring newer treatment are some of the impacting factors that drives the market growth. Moreover, special designation such as orphan drug designation and fast track designation are considered a positive indicator for rise in market growth.
Initiatives by the governments will drive the growth of the market
Governments of different countries such as the U.K., Canada, New Zealand, Australia, and Argentina and the European Union are expected to accelerative initiatives for the treatment of celiac disease. These governments could provide a strong boost to the global celiac disease drugs market while riding on therapeutics offered at subsidized prices, increasing awareness among the people, and funds offered to research and development activities. Canada and Argentina are predicted to impose labeling restrictions on gluten-rich packaged foods and also those free of gluten to keep the spread of celiac disease at bay. Initiatives such as the National Program for the Detection and Control of Celiac Disease by Argentina are anticipated to be a good step taken to counter the disease.
The rise in demand from millennials, increase in the incidence of celiac disease
It is hard to maintain 100% gluten-free diet and accidental gluten cross-contamination cannot be avoided, so researchers such as ImmunogenX are focused on finding alternative therapies and possibly even a cure for the disorder. Major pipeline molecules include bl-7010 (binds gluten so it is not absorbed), larazotide acetate (interrupt the immediate or delayed effects of gluten on the cells lining the intestine), and vedolizumab (interrupt the immune reactions). Rise in demand from millennial, rise in research and development expenditure, and growth in awareness about celiac disease are factors fuelling the growth of the celiac disease market.
The high cost of a gluten-free diet is likely to hinder the market growth
However, high cost of gluten-free diet, lack of confidence of pipeline molecules, and the frequency of the disease being undiagnosed or misdiagnosed as an allergy are restraining the celiac disease market growth. Many low-income earning people can not afford these diets. Also, many underdeveloped areas do have not the proper infrastructure to process the gluten-free diet.
COVID-19 Impact Analysis
To date, there have been no studies or reports suggesting patients with celiac disease are at increased risk of severe illness from COVID-19 compared to patients without celiac disease. The Celiac Disease Foundation Medical Advisory Board states that celiac disease patients in general are not considered to be immunocompromised. A small proportion of celiac disease patients with severe malnutrition and weight loss, the rare complication of Type 2 refractory celiac disease, on immunosuppressive medications, or with other serious illnesses, may be at increased risk of severe illness from COVID-19 and should consult with their physicians. The Celiac Disease Foundation Medical Advisory Board does not consider occasional gluten exposure from cross-contact to put a patient with celiac disease at increased risk of severe illness from COVID-19, but cautions that patients should adhere to a strict, gluten-free diet for overall health. The pandemic will not effect the market in the forecast period.
The diarrhea segment is expected to grow at the fastest CAGR during the forecast period (2020-2028)
Diarrhea is a bowel movement (stool) that is loose and watery. It is one of the common, non-serious conditions and can be treated with over-the-counter medicines. Numerous people experience diarrhea once or twice a year. It is estimated that globally, approximately 2 billion cases of diarrheal diseases occur each year, and about 1.9 million children (below five years of age), mostly found in developing countries, die from diarrhea. All these factors are contributing and showing the impact of celiac disease.
In one small study, 79% of celiac patients reported experiencing diarrhea prior to treatment. Following treatment, just 17% of patients continued to have chronic diarrhea. Another study of 215 people noted that diarrhea was the most frequent symptom of untreated celiac disease. For many patients, diarrhea was reduced within a few days of treatment, but the average time to fully resolve symptoms was four weeks.
Decreased energy levels and fatigue are prevalent in those with celiac disease. One study of 51 celiac patients found that those who were untreated had significantly more severe fatigue and fatigue-related problems than those on a gluten-free diet. Another study found that those with celiac disease were more likely to have sleep disorders, which could contribute to fatigue. Additionally, untreated celiac disease can cause damage to the small intestine, resulting in vitamin and mineral deficiencies that may also lead to fatigue. These factors are driving the growth of the market in the forecast period.
North America region holds the largest market share global Celiac Disease Drugs market
North America region is dominating the global celiac disease drugs market accounted for the largest market share in 2019, owing the presence of refined healthcare expenditure and increased patient awareness level as well as high prevalence of celiac diseases. Additionally, increase in demand for advance treatment, increased health care expenditure, and high diagnosis rate. Asia Pacific is an emerging market due to developing health care infrastructure and increased government expenditure along with patient awareness and patient pool for celiac disease.
Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales drives the growth rate over the forecast period.
The celiac disease drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Innovate Biopharmaceuticals, Teva Pharmaceutical Industries Ltd, ImmunogenX, LLC, Amgen, ChemoCentryx, Inc, Anokion SA, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, ImmusanT, Inc, BioLineRx Ltd, and Takeda Pharmaceutical Company Limited, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the celiac disease drugs market globally.
Celiac Disease Drugs Market Key Companies to Watch
Innovate Pharmaceuticals Limited
Overview: Innovation Pharmaceuticals develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company focuses on the development of compounds, including INN-202 (larazotide acetate) is a drug for celiac which is in pipeline that uses a potent digestive enzyme that appears to be able to break down gluten before your immune system can react to it. The results of phase II clinical trial were promising and demonstrated that the drug was both safe and tolerable. The drug's MOA both decreases the permeability of the intestines while tempering the movement of autoimmune antigens into the intestines. The company incorporated on 9 September 2014 with the registered office located in Manchester, Greater Manchester. Innovate Pharmaceuticals Limited has been running for 6 years. There is currently 1 active director according to the latest confirmation statement submitted on 6th February 2020.
Product Portfolio: The Company’s portfolio comprised of anti-cancer agents, small molecule therapies to treat cancer, antibiotics, and inflammatory disease, asthma drugs and others.
Key Developments: - In August, 2019 Innovate Biopharmaceuticals, Inc. announced that it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001. This marks the first time any company has dosed a patient in a Phase 3 trial for celiac disease.
Get your free sample proposal with a single click!